A. Corey - Concepedia

Author

A. Corey

Human Genome Sciences (United States)

Also Known As

A. Corey, A.E. Corey, Alfred Corey, Alfred E Corey, Alfred E. Corey

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Human Genome Sciences (United States)Fox Chase Cancer Center Princess Margaret Cancer Centre Procter & Gamble (United States)Hamilton Regional Laboratory Medicine Program

About

A. Corey is an author at Human Genome Sciences (United States) specializing in medicine, pharmacology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	229
2	Pharmacology	9	9	194
3	Immunology	8	8	160
4	Pathology	4	4	91
5	Microbiology	1	1	32

A. Corey

Publications

Citations

H-Index

Page 1

	Year	Citations
Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1 Anthony W. Tolcher, Monica Mita, Neal J. Meropol, Journal of Clinical Oncology	2007	311
Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers Ruth Plummer, Gerhardt Attard, Simon Pacey, Clinical Cancer Research	2007	243
A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies Sébastien J. Hotte, Hal W. Hirte, Eric X. Chen, Clinical Cancer Research	2008	189
HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study Laura Q.M. Chow, S. Gail Eckhardt, Daniel L. Gustafson, Journal of Clinical Oncology ImmunologyPathologyCell DeathImmunotherapeuticsPhase 1	2006	34
Bacillus anthracis Protective Antigen Kinetics in Inhalation Spore-Challenged Untreated or Levofloxacin/ Raxibacumab-Treated New Zealand White Rabbits A. Corey, Thi‐Sau Migone, Sally D. Bolmer, Toxins ToxinologyMicrobial PathogensAntimicrobial ChemotherapyPa KineticsMedical Microbiology	2013	32
A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors A. W. Tolcher, M. Mita, Amita Patnaik, Journal of Clinical Oncology ApoptosisImmunologyCell DeathImmunotherapeuticsImmunotherapy	2004	25
Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL) Lyly Le, Holger W. Hirte, Sébastien J. Hotte, Journal of Clinical Oncology ApoptosisImmunologyImmunoeditingCell DeathPathology	2004	25
Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing A. Corey, Hussein R. Al‐Khalidi, Christopher P. Brezovic, Biopharmaceutics & Drug Disposition	1999	24
Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies Simon Pacey, Ruth Plummer, Gerhardt Attard, Journal of Clinical Oncology ApoptosisImmunologyCell DeathPathologyPharmacotherapy	2005	22
Effect of Age and Gender on Azimilide Pharmacokinetics After a Single Oral Dose of Azimilide Dihydrochloride A. Corey, Jeffrey R. Agnew, James J. Bao, The Journal of Clinical Pharmacology Drug SafetyMedicinal ChemistryPharmacological StudyAzimilide PharmacokineticsMedicine	1997	20

Page 1